Explore

Trendline Trendline
Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT

Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT

Spruce Biosciences Strengthens Financial Position Ahead of Potential U.S. Launch of TA-ERT
Trendline Trendline
Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB

Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB

Spruce Biosciences Reports Financial Results and Advances TA-ERT Program for MPS IIIB
Trendline Trendline
Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI

Savara Reports Increased Losses in Q1 2026 Amid Regulatory Milestones for MOLBREEVI
Trendline Trendline
Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy

Longeveron Reports Q1 2026 Financial Results and Strategic Developments in Stem Cell Therapy
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Savara Reports First Quarter Financial Results Highlighting MOLBREEVI Development Progress

Savara Reports First Quarter Financial Results Highlighting MOLBREEVI Development Progress

Savara Reports First Quarter Financial Results Highlighting MOLBREEVI Development Progress
Trendline Trendline
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107

INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107

INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
Trendline Trendline
CytoSorbents Reports Increased Revenue Amidst Financial Losses in Q1 2026

CytoSorbents Reports Increased Revenue Amidst Financial Losses in Q1 2026

CytoSorbents Reports Increased Revenue Amidst Financial Losses in Q1 2026
Trendline Trendline
Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress

Atara Biotherapeutics Reports First Quarter 2026 Financial Results Highlighting Operational Progress
Trendline Trendline
Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026

Agenus Inc Reports Significant Revenue Growth and Profit in Q1 2026
Trendline Trendline
Adagio Medical Reports Q1 2026 Financial Results and Advances in Cardiac Arrhythmia Treatment

Adagio Medical Reports Q1 2026 Financial Results and Advances in Cardiac Arrhythmia Treatment

Adagio Medical Reports Q1 2026 Financial Results and Advances in Cardiac Arrhythmia Treatment
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358